Last edition
News about Global Pharma
Canadian biotechnology company Cardiol Therapeutics has announced topline results from its ARCHER Phase II clinical trial evaluating CardiolRx in patients with acute myocarditis.
Global Pharma | 08/08/2025 | By Dineshwori | 210
The US Food and Drug Administration (FDA) has granted accelerated approval for Jazz Pharmaceuticals' Modeyso (dordaviprone) for the treatment of adult and pediatric patients 1 year of age and older with H3 K27M-mutant diffuse midline glioma – a rare and highly aggressive brain tumour – with progressive disease following prior therapy.
Global Pharma | 08/08/2025 | By Dineshwori | 500
Freenome Partners with Exact Sciences to Commercialise Blood-Based Colorectal Cancer Test
Freenome has entered into an exclusive license agreement with Exact Sciences to advance the commercialisation of its colorectal cancer (CRC) blood-based screening test.
Global Pharma | 08/08/2025 | By Dineshwori | 844
Emcure Pharma Delivers Robust Performance Across All Businesses in Q1FY26: Satish Mehta
Emcure Pharmaceuticals reported strong financial results for the first quarter of FY26, demonstrating impressive growth in both domestic and international businesses.
Global Pharma | 07/08/2025 | By Dineshwori | 517
Celltrion Secures US FDA Approval for Expanded Indication for AVTOZMA
Celltrion has received FDA approval for an expanded indication of AVTOZMA IV (tocilizumab-anoh) to treat cytokine release syndrome (CRS), achieving full indication parity with reference biologic ACTEMRA IV in the US.
Global Pharma | 07/08/2025 | By Mrinmoy Dey | 218
Sandoz Reports Strong H1 2025 Results, Accelerated Growth in Biosimilars and Generics
Sandoz has reported strong financial results for the first half of the financial year 2025, with the company’s net sales reaching USD 5.2 billion. Growth accelerated in the second quarter, driven by solid performance across both the generics and biosimilars businesses.
Global Pharma | 07/08/2025 | By Dineshwori | 809
Intas Pharmaceuticals Acquires UDENYCA from Coherus BioSciences
Intas Pharmaceuticals, along with its global subsidiaries operating under the Accord brand, has acquired UDENYCA (pegfilgrastim-cbqv) from Coherus BioSciences, strengthening its global biosimilar portfolio and strengthening its position in the pegfilgrastim market.
Global Pharma | 07/08/2025 | By Mrinmoy Dey | 291
Kashiv Biosciences, MS Pharma Partner to Commercialise Xolair Biosimilar in MENA Region
Kashiv BioSciences and MS Pharma have entered into an exclusive licensing and supply agreement for the commercialization of ADL-018, Kashiv’s biosimilar candidate to XOLAIR (bOmalizumab) in the Middle East and North Africa (MENA) region.
Global Pharma | 07/08/2025 | By Dineshwori | 262
Sanofi Acquires Vigil Neuroscience, Strengthens Neurodegenerative Disease Pipeline
Sanofi has completed its acquisition of Vigil Neuroscience, thereby strengthening its early-stage pipeline in neurology with the addition of VG-3927, an experimental drug candidate for Alzheimer's disease.
Global Pharma | 07/08/2025 | By Dineshwori | 327
Pharmexcil Invites Indian Pharma Companies to Explore Opportunities in Mexico at Virtual Meet
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has invited its member companies to participate in a virtual meet on "Mexico: Expansion Opportunities for the Indian Pharmaceutical Industry."
Global Pharma | 06/08/2025 | By Dineshwori | 384
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy